Bharat Biotech International Limited
Healthcare · Pharma (Vaccines & Biologics)
Awaiting a verified source quote. No third-party quote is on record for this company yet, so there is no indicative price to show — and we would rather leave it blank than print a number we cannot stand behind. Our team can confirm the current dealable level directly.
Indicative private-market reference — not an exchange quote. Not investment advice.
- Implied valuation
- Not available
- Revenue growth
- Not disclosed
- EBITDA margin
- Not disclosed
- Prospera Score
- Not yet scored
What the market says, and what we know.
Two separate things, deliberately shown side by side: a sourced private-market price reference, and the depth of research that actually stands behind this company today.
No third-party quote has been sourced for this company yet, so there is no market reference to show. Ask us to check the current level and we will come back with what the market is actually doing.
- Research Universe — availableCatalogued as a strategically relevant private-market company.
- Basic Research — availableBusiness and ownership facts verified against primary sources — 2 sourced records on file.
- Deep Research — not availableNot started. No financials, no implied valuation and no Prospera Score exist for this company.
- Prospera Recommendation — not availableNo Prospera view has been published. Presence in the universe is not a recommendation.
Indicative Private-Market Price History
Real, dated third-party observations only — plotted where they exist, never interpolated, extended or carried forward. This is a record of private-market sightings, not a live exchange chart.
Price history not available. No dated third-party quotes have been sourced for this company yet.
The business, in plain English.
Assembled only from records that exist for this company. Anything not disclosed says so.
- Founded
- 1996
- Headquarters
- Hyderabad, Telangana
- Sector
- Healthcare · Pharma (Vaccines & Biologics)
- Promoters
- Krishna Ella, Suchitra Ella
What it does
Bharat Biotech is an Indian biotechnology company that develops and manufactures vaccines and biotherapeutics, most notably Covaxin, India's first indigenously developed COVID-19 vaccine. It was founded in Hyderabad's Genome Valley in 1996 by Dr. Krishna Ella, who remains Chairman and Managing Director alongside co-founder Suchitra Ella, and the company remains privately held by the Ella family. As of FY22 the company reported revenue of about Rs. 8,148 crore.
Source: Bharat Biotech (official) / WikipediaWhy it matters
Competes domestically with Serum Institute of India and internationally with global vaccine developers in the biologics and vaccines space.
Source: Not attributedOwnership structure
Privately held by Krishna Ella (Chairman & Managing Director) and co-founder Suchitra Ella
Promoters & principal holders: Krishna Ella, Suchitra Ella
Private-market context
Unlisted, privately held by the founding family; no public IPO plans announced
What to understand before investing
- Unlisted shares can be difficult to sell. There may be no continuous market and no guaranteed buyer at the price you see.
- Any price shown here is an indicative private-market reference, not an exchange quote and not an executable price.
- An expected IPO may be delayed, repriced or never happen at all.
- A good company can still be a poor investment at the wrong valuation.
Research is not yet complete for this company.
We would rather say that plainly than publish a page that looks finished.
No financials, no implied valuation and no peer comparison have been researched for this company yet.
No Prospera Private Market Score and no Prospera view exist. Being in our universe is not a recommendation, and we will not manufacture one to fill this space.
What you can rely on above is what has actually been verified: the company's identity and business facts, any sourced price observations on record, and any risks that have been documented. If you want us to prioritise deeper work here, ask — that is genuinely how the queue gets set.
What could go wrong.
Documented, per-company risks — grouped by the categories the research itself recorded. There is no risk score here, because we do not compute one.
Business
1 recorded riskBharat Biotech's flagship COVID-19 vaccine Covaxin faced public scrutiny in India over the pace and transparency of efficacy-data disclosure during the pandemic, which drew regulatory and media attention to its clinical-trial practices.
Source: Contemporaneous Indian media coverage, 2021-22What's happened, and why it matters.
Dated, sourced events only — recorded as they were reported, in reverse order of significance to a private-market holder.
No corporate events have been documented for this company yet.
Everything traceable.
Every figure on this page comes from one of the records below. Where a source published a link, it is here.
| Field | Source | As of |
|---|---|---|
| Business Description | Bharat Biotech (official) / Wikipedia | Not disclosed |
| Competitive Position | Not attributed | Not disclosed |
Interested in Bharat Biotech International Limited?
Every option below opens a conversation with a person at Prospera. Nothing here places, reserves or executes an order.
We will come back with the current dealable level, the available lot size and what the process actually involves. Indicative prices shown on this page are private-market references, not executable quotes.